An in utero paternal CD34
Successful treatment for SCID has been accomplished in a very small number of cases by in utero fetal liver transplants or BM CD34 + cells transplantation. 1 In patients with haploidentical (ie paternal) T cell-depleted CD34
+ BM cell transplantation, we and others have previously demonstrated lymphoid engraftment and restoration of T cell function early after in utero BMT. [2] [3] [4] However, there is limited information on the long-term immune reconstitution, mainly on humoral immune responses in patients with SCID and in utero BMT. normal B cell function requires T-B cell co-operation and it is delayed when compared to T cell reconstitution. Full restoration of B cell function is achieved in 60-70% of B+ SCID patients only several years after HLA haploidentical T cell-depleted BMT. 5 The lack of adequate levels of serum Igs in those patients who do not achieve B cell reconstitution requires IVIG treatment.
In this study, we present data of the 3-year follow-up on B cell reconstitution in one SCID patient who was treated with in utero haploidentical BMT.
Materials and methods

Patient
Immunological analyses which were performed prior to and immediately after in utero BMT are described elsewhere. 4 Briefly, in September 1997, a T-B+NK+ SCID prenatal diagnosis was performed on a male fetus at week 23 of gestation. The parents were related and they had a previously affected T-B+NK+ SCID son (unknown molecular etiology). Paternal BM CD34 + cells were purified and two i.p injections (the second infusion together with ex vivo generated BM stromal cells) were performed in the Spedali Civili, Brescia, Italy. 4 The donor did not have antibodies to hepatitis B virus (HBV) and he had never been vaccinated against HBV. The T cell function in the patient developed at month 4 post transplantation and it has remained normal since then. Serum IgG levels progressively fell within the first months of life, IVIG therapy (400 mg/kg every 4 weeks, Endobulin IV; Baxter, Vienna, Austria) was started when IgG levels dropped below 200 mg/dl (Figure 1 ). The patient's growth and development have always been normal. He has presented several upper respiratory infections, two episodes of gastroenteritis and two episodes of otitis media. The patient received prophylaxis with ketoconazole, acyclovir and co-trimoxazole until he was 6 months old. He has completed the following vaccination schedule: HB, DTP, Hib and eIPV immunizations were administered at 3 months of age; HB and eIPV at 4 months of age, DT, Hib and eIPV at 6 months of age, HB and meningococcal A+C vaccine when he was 1 year old, and DT and Hib at 19 months of age. He was immunized by mistake with MMR at 29 months of age, receiving as prophylaxis an IVIG infusion (Figure 1 ). At present, the patient is 4 years old; he is asymptomatic and with excellent health, 90th percentile for height and weight, and without any therapy.
The immunological studies were undertaken with the approval of the Ethics Committee of the Hospital General Universitario Gregorio Marañón, and written informed consent was obtained from the patient's parents.
Isolation of PBMC
Cells for chimerism, lymphoproliferative and ELISPOT assays were isolated from fresh heparin-anticoagulated blood by density gradient centrifugation (Lymphoprep, Nicomed Pharma, Oslo, Norway). Cells for lymphoproliferative assay were obtained 20 days after a recall rHBsAg immunization (fourth dose), and those for the ELISPOT assay 7 and 20 days after this rHBsAg immunization.
Evaluation of engraftment
Chimerism analysis was performed by typing of the 3Ј apoB VNTR region. 6 The patient's PBMC were previously fractionated into CD3
+ , CD56 + , CD19 + and CD14 + cells by using standard immunomagnetic purification methods (Miltenyi Biotec, Auburn, CA, USA). Purity of the cellular fractions was higher than 90% as assessed by flow cytometry. Genomic DNA was extracted from donor PBMC and from host PBMCs and fractions. Amplification of apoB VNTR region was carried out using 5Ј-ATGGAAACGGAGAAATTATG-3Ј as 5Ј primer and 5Ј-CCTTCTCACTTGGCAAATAC-3Ј as 3Ј primer. DNA from 1.5 × 10 5 T cells or 10 5 PBMC and the other cellular fractions were used for each reaction. Prior to addition of the Taq polymerase, the reaction mixture was boiled for 7 min. Annealing and extension was carried out for 6 min at 62°C and denaturating was carried out for 1 min at 94°C for a total of 30 extension-denaturation cycles. Electrophoresis of the amplification products was performed on 2% agarose gel and the amplified alleles were visualized with ethidium bromide.
Lymphocyte immunophenotyping
This was performed by direct immunofluorescence and flow cytometry analysis (Becton Dickinson, Mountain View, CA, USA). Conjugated moAb anti-CD3 (FITC)/CD19 (PE)/CD45 (PercP) from Becton Dickinson were used for the evaluation of B lymphocytes.
Immunoglobulin, isohemagglutinin and specific antibody quantitation
Patient serum was incubated with specific Ab to IgG, IgA and IgM and the resultant immune complexes were measured by a nephelometer (Beckman, Brea, CA, USA). Isohemagglutinin titers were measured by standard methodology. Anti-tetanus toxoid Ab titers were assayed by ELISA (The Binding Site, Birmingham, UK). For the monitoring of serum-specific Ab responses to hepatitis B surface antigen (anti-HBs), pre-immunization and 7, 20 and 50 days post-immunization serum samples were quantitated within the same assay by a standard microparticle enzyme immunoassay (Abbott AxSYM System, Weisbaden, Germany).
Detection of Anti-HBsAg Ab secreting cells (HBs AbSC)
This was determined by the ELISPOT method described by Böcher et al, 7 with slight modifications. Polyvinylidene difluoride-bottom 96-well MultiScreen IP filtration plates (Millipore, Bedford, MA, USA) were coated at 100 l per well with carbonate buffer (pH 9.6) containing 10 g/ml of purified recombinant HBsAg (kindly provided by SmithKline Beecham, Rixensart, Belgium) and incubated overnight at 4°C. Wells coated with BSA were used as negative controls. After washing with sterile distilled water, plates were blocked with 200 l per well of RPMI 1640 medium supplemented with 3% BSA (RPMI-BSA) for 1 h at 37°C. Blocking medium was discarded and PBMC were added at 2.5 × 10 5 per well in 200 l of RPMI-BSA. After incubation for 6 h at 37°C in a humid atmosphere with 5% CO 2 , the plates were washed with PBS containing 0.05% Tween 20 (PBS-T) and incubated for 1 h at 37°C with a peroxidase-conjugated rabbit anti-human IgG (Dako, Glostrup, Denmark) diluted 1:1000 in PBS containing 1% BSA. The plates were washed with PBS-T and staining was carried out by adding substrate solution containing 3-amino-9-ethyl-carbazole. After 20-30 min the reaction was stopped by rinsing water. Granular red spots were enumerated with a dissection microscope and results were expressed as IgG anti-HBs AbSC per 10 6 PBMC.
Lymphoproliferative assay
2 × 10 5 PBMC/well were seeded in RPMI 1460 medium containing antibiotics, 2 mm glutamine and 10% pooled human AB serum in 96-well U-bottom plates (Costar, Corning, MD, USA); triplicates with increasing concentrations of purified recombinant HBsAg were set from 0.5 to 5 g/ml. PBMC were incubated at 37°C, 5% CO 2 for 5 days and on the sixth day of culture 1 Ci of H 3 Thy (Amersham, Bucks, UK) was added. Cultures were harvested 18 h later. Radioactivity was measured in a beta counter (MicroBeta TRILUX, Wallac Oy, Turkey, Finland). Figure 2 shows the chimerism study performed 33 months after in utero BMT. There is engraftment of donor T cells (along with a small number of autologous T cells), while circulating B cells, NK cells and monocytes are of host origin. This pattern of engraftment has been stable since the first study performed at 9 months post in utero BMT (data not shown).
Results
Serum concentrations of IgM have been normal since birth (Figure 1 ). IgA levels remained р20 mg/dl until 14 months of age when the levels started to increase reaching levels greater than 50 mg/dl month 20 post in utero BMT. IgG levels increased from month 5 to month 22 of age, the period in which the patient was receiving IVIG. After IVIG withdrawal, the IgG levels remained within the normal range (the most recent value at month 35 was 948 mg/dl IgG).
Serum isohemagglutinin titers were first assessed and found to be positive at month 9 post transplantation (anti-A: 1/4, anti-B: 1/2), showing the highest values (anti-A: 1/128, anti-B: 1/32) at month 30 of age. Eight months after the last IVIG infusion, specific Ab titers to TT were detected (16 g IgG1/dl).
Circulating absolute B cell numbers remained within normal age-matched levels throughout the follow-up (641, 807, 484 and 480 CD19 + cells/l at 7, 15, 27 and 33 months post in utero BMT, respectively). + cells.
Bone Marrow Transplantation
Seven days after immunization of the patient with rHBsAg, peripheral IgG anti-HBs AbSC were present, with a median number of 54/10 6 PBMC. Children and adult healthy controls were also tested 7 days after immunization with rHBsAg and showed detectable but lower frequencies of anti-HBs AbSC (2 ± 1/10 6 PBMC). No anti-HBs AbSC were detected 20 days after HBsAg immunization either in the patient or in the healthy controls (data not shown). The presence and concentrations of specific serum anti-HBsAg Ab levels were also studied in this patient: serum IgG antiHBsAg levels pre-immunization and at 7, 20, and 50 days post immunization were 13 291, 35 475, 103 920 and 66 650 mIU/ml, respectively, showing at 20 days post immunization a 7.8-fold increase over the baseline levels.
The specific T cell lymphoproliferative response of the patient's PBMC to rHbsAg (1 g/ml) showed an stimulation index (SI) of 4. 10 (35 282 c.p.m.) . The lymphoproliferative response of the adult healthy control included in the study showed an SI of 3.03 (18 224 c.p.m.).
Discussion
We provide evidence of complete immune reconstitution following in utero transplantation in a T-B+NK+ SCID patient. Clinical experience with in utero CD34
+ cell transplantation is still poor and successful cases have been limited to T-B+NK-SCID affected fetuses, a more common form of presentation of primary immunodeficiency. Other approaches using fetal liver transplants have also been reported in two patients with HLA deficiency and a SCID fetus. 8 Our data show that the restoration of a fully functional immune system after in utero BMT is not delayed as compared to T cell-depleted, haploidentical post-natal BMT performed in SCID patients. 5 Evidence of B cell function in this in utero BMT is demonstrated by IgA levels, production of isohemagglutinins and specific Ab responses evaluated by circulating antiHBsAg Ab secreting cells and serum anti-HBsAg IgG following HBsAg immunization. Along with the B cell function study, we have detected HBsAg-specific T cell lymphoproliferative responses. This antigen-specific response cannot be related to the transfer of donor memoryspecific T cells, since the donor was seronegative for HBV and he has never been immunized with HBsAg. The response could be due to the generation in the recipient of HbsAg-specific T cells which differentiated in his thymus. Other authors have found that NK+ SCID patients who do not receive pretransplant cytoreduction have a poor clinical and immunological outcome. 9 However, the T cell engraftment and restoration of immune function in this SCID patient have occurred in the presence of autologous NK cells and without any pretransplant treatment.
Approximately 30% of T-B+ SCID patients treated with post-natal HLA non-identical BMT do not develop a normal B cell function. It has been suggested that in T-B+ SCID, lack of Ab responses following haploidentical, T cell-depleted BMT could be due to intrinsic B cell defects and/or to the lack of engraftment of donor B cells. 10 The phenotype T-B+NK+ is rather unusual, 11 the majority of B-positive SCID cases being NK negative. Although the molecular basis of the immunodeficiency in our patient remains unknown, the results suggest that once T cell function has been restored the primary defect does not affect B cells. We have not excluded the presence of microchimerism (р3% of donor cells) within the B cell population. 12 Therefore, the humoral immune responses demonstrated in the patient could be due to the activation of allogeneic B cells. However, it seems unlikely that such a small number of B cells could account for the normal levels of serum Igs.
We have found a good T-B cell co-operation in this patient demonstrated by the strong specific humoral responses. Co-operation between donor origin T cells and host origin B cells in SCID following post-natal BMT has been recently demonstrated by the presence of autologous allotypic determinants and B cell phenotypic subpopulations. 10 This T-B cell co-operation might be the result of the positive selection of thymocytes derived from the donor CD34 + cells by host HLA molecules expressed on the thymic epithelium.
Quantification of the concentrations of individual Ig classes by conventional serological methods presents several limitations derived from the rate of synthesis and catabolism of these molecules. Moreover, transplacentally acquired Ig and/or exogenous IVIG, which occurs frequently in the SCID-BMT setting, does not allow an estimation of the Ig pool contributed by the child's immune system to be made. The single cell functional immunoassay ELISPOT provides accurate information on Ig production at a cellular level by detecting Ab secreting cells. 13, 14 The use of ELISPOT has enabled us to show active and specific Ab production by B cells of the BMT recipient, and may be a clinically useful method for the study of the humoral immune responses in patients with BMT.
The data support in utero BMT as an alternative therapeutic procedure to selective abortion or to post-natal BMT in SCID disorders following prenatal diagnosis. More cases of in utero BMT in other fetuses with SCID are necessary in order to confirm the efficacy of the procedure, in particular in SCID patients bearing the T-B+NK+ phenotype.
